Medicare人群中高级别子宫内膜癌辅助治疗的差异
本研究利用Medicare-linked SEER数据库分析2000至2015年接受手术的高级别子宫内膜癌患者,发现非西班牙裔黑人患者的5年总生存期显著差于西班牙裔和非西班牙裔白人患者(30.9个月 vs 51.0个月 vs 53.6个月)。西班牙裔女性治疗延迟风险增加71%(OR 1.71,95%CI 1.23-2.38),非西班牙裔黑人种族独立预测FIGO II期及以上患者辅助治疗使用减少(OR 1.32,95%CI 1.04-1.68)。治疗延迟在多变量分析中未独立预测更差的1年或5年生存。
要点
- 非西班牙裔黑人高级别子宫内膜癌患者5年总生存期显著差于西班牙裔和非西班牙裔白人患者。
- 西班牙裔女性治疗延迟风险增加71%(OR 1.71,95%CI 1.23-2.38)。
- 非西班牙裔黑人种族独立预测FIGO II期及以上患者辅助治疗使用减少(OR 1.32,95%CI 1.04-1.68)。
核心结论
- 非西班牙裔黑人种族预测所有分期中更差的5年生存,并与FIGO II期或更高期别高级别子宫内膜癌中辅助治疗的省略相关。
- 在未调整分析中,经历治疗省略或延迟的患者总生存更差,但这些因素在多变量分析中未独立相关。
- 本研究提示种族和民族与高级别子宫内膜癌患者辅助治疗的类型和时机独立相关。
研究设计与样本
- 使用Medicare-linked Surveillance, Epidemiology, and End Results数据库识别2000至2015年间以手术为主要治疗的高级别子宫内膜癌女性。
- 纳入子宫3级子宫内膜样腺癌、癌肉瘤、透明细胞癌或浆液性癌患者。
- 排除不认同为白人种族、黑人种族或西班牙裔民族的患者。
- 共12,201名女性符合研究纳入标准。
主要发现
- 非西班牙裔黑人患者的5年总生存期显著差于西班牙裔和非西班牙裔白人患者(30.9个月 vs 51.0个月 vs 53.6个月)。
- 接受辅助治疗的7282名患者中约632名(8.6%)经历治疗延迟。
- 治疗延迟≥12周在种族和民族间有显著差异(P=.034),西班牙裔12%、非西班牙裔黑人9%、非西班牙裔白人8%经历延迟。
- 调整并发症数量、年龄、组织学(子宫内膜样 vs 非子宫内膜样)、FIGO分期、婚姻状况、合并症数量、手术方式、淋巴结清扫和城乡代码后,西班牙裔女性所有分期疾病治疗延迟风险增加71%(OR 1.71,95%CI 1.23-2.38)。
- 同一模型中,非西班牙裔黑人种族独立预测FIGO II期及以上辅助治疗使用减少(OR 1.32,95%CI 1.04-1.68)。
关键数值与推荐
- 治疗延迟定义为辅助治疗延迟≥12周。
- 多变量模型调整因素包括并发症数量、年龄、组织学(子宫内膜样 vs 非子宫内膜样)、FIGO分期、婚姻状况、合并症数量、手术方式、淋巴结清扫和城乡代码。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Black women experience worse survival effects with high-grade endometrial cancer. Differences in adjuvant treatment have been proposed to be major contributors to this disparity. However, little is known about the differences in type or timing of adjuvant treatment as it relates to race and ethnicity in the Medicare population. OBJECTIVE: This study aimed to examine patterns of adjuvant therapy and survival for non-Hispanic Black women vs non-Hispanic White women and Hispanic women who have undergone surgery for high-grade endometrial cancer in the Medicare population. STUDY DESIGN: We used the Medicare-linked Surveillance, Epidemiology, and End Results database to identify women who underwent surgery as a primary treatment for uterine grade 3 endometrioid adenocarcinoma, carcinosarcoma, clear-cell carcinoma, or serous carcinoma between the years 2000 and 2015. Women who did not identify as White or Black race or Hispanic ethnicity were excluded. Multinomial logistic regression was used to estimate odds ratios and 95% confidence intervals for receiving a treatment delay or not receiving adjuvant treatment (compared with those who received adjuvant treatment within 12 weeks) adjusted for clinical and demographic characteristics. Overall survival was stratified by race and ethnicity, route of surgery, operative complications, and type and timing of adjuvant therapy, which were analyzed using the Kaplan-Meier method. Cox proportional-hazards regression was used to estimate the hazard ratio of death by race and ethnicity adjusted for known predictors and surgical outcomes and adjuvant therapy patterns. RESULTS: A total of 12,201 women met the study inclusion criteria. Non-Hispanic Black patients had a significantly worse 5-year overall survival than Hispanic and non-Hispanic White patients (30.9 months vs 51.0 months vs 53.6 months, respectively). Approximately 632 of 7282 patients (8.6%) who received adjuvant treatment experienced a treatment delay. Delay in treatment of ≥12 weeks was significantly different by race and ethnicity (P=.034), with 12% of Hispanic, 9% of non-Hispanic Black, and 8% of non-Hispanic White women experiencing a delay. After adjustment for the number of complications, age, histology (endometrioid vs nonendometroid), International Federation of Gynecology and Obstetrics stage, marital status, comorbidity count, surgical approach, lymph node dissection, and urban-rural code, Hispanic women had a 71% increased risk of treatment delay (odds ratio, 1.71; 95% confidence interval, 1.23-2.38) for all stages of disease. In the same model, non-Hispanic Black race was independently predictive of decreased use of adjuvant treatment for the International Federation of Gynecology and Obstetrics stage II and higher (odds ratio, 1.32; 95% confidence interval, 1.04-1.68). Non-Hispanic Black race, number of perioperative complications, and nonendometrioid histology were predictive of worse survival in univariate models. Treatment delay was not independently predictive of worse 1- or 5-year survival at any stage. CONCLUSION: Non-Hispanic Black race was predictive of worse 5-year survival across all stages and was associated with omission of adjuvant treatment in International Federation of Gynecology and Obstetrics stage II or higher high-grade endometrial cancer. In unadjusted analyses, patients who experience treatment omission or delay experienced poorer overall survival, but these factors were not independently associated in multivariate analyses. This study suggests that race and ethnicity are independently associated with the type and timing of adjuvant treatment in patients with high-grade endometrial cancer. Further efforts to identify specific causes of barriers to care and timely treatment are imperative.
引用
- Corey L, Cote ML, Ruterbusch JJ, et al. Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population. Am J Obstet Gynecol. 2021. PMID: 34736911. doi:10.1016/j.ajog.2021.10.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。